Pelvic Congestion Syndrome Treatment market Buoyed by Surging Genital Cancer Research

Growing incidences of prostate and ovarian cancers are increasing the frequency of pelvic discomfort, prompting players to introduce advanced surgical and medical treatment alternatives, providing significant traction

Growing incidences of prostate and ovarian cancers are increasing the frequency of pelvic discomfort, prompting players to introduce advanced surgical and medical treatment alternatives, providing significant traction

Fact.MR, Rockville MD: Ongoing study on the global pelvic congestion syndrome treatment market predicts substantial gains across 2021, underpinned by planned pipeline studies to discover advanced trunk oncology therapies, with preference for primary-grade treatment experiencing a noteworthy upswing. Recessionary downswings induced by COVID-19 had a negligible impact on the market, with treatments for pelvic floor dysfunctions remaining unceasing.

According to the American Cancer Society, ovarian cancer ranks 5th in cancer fatalities among women. Projections for 2021 suggest the emergence of over 21,000 new diagnoses and a fatality rate exceeding 13,000. Fortunately, unwavering research initiatives has generated a broad consensus that this incidence will likely wane in the long-run, thereby, generating confidence amongst the medical fraternity.

Prominent players are introducing a slew of innovative therapeutic approaches to address pelvic dysfunction disorders, leading to the emergence of various revenue pools. For instance, in 2018, Siemens Healthineers introduced an advanced molecular imaging technique for the detection of bladder invasion and pelvic lymph node metastases amongst patients suffering from prostate cancer.

“Key pelvic congestion syndrome treatment players are leveraging advanced diagnostic solutions which incorporate precision based techniques for the effective detection and subsequent eradication of anomalies leading to pelvic dysfunction and discomfort,” says the Fact.MR analyst.

Request a report sample to gain comprehensive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=3127

Key Takeaways from Fact.MR’s Pelvic Congestion Syndrome Treatment Study

  • Growth frontiers to open up in primary pelvic congestion syndrome treatment through 2021
  • By medication, analgesic treatment to remain highly preferred amid growing need for non-invasive therapies
  • Emergence of specialized treatment delivery centers to uplift prospects for gynecology clinics
  • US to generate wide revenue pools for hormonal pelvic congestion syndrome treatment medications
  • Development of targeted drugs to treat ovarian cancers to stimulate pelvic congestion syndrome treatment market in the UK
  • Growing healthcare spending to stimulate pelvic congestion syndrome treatment approaches in the future
  • India to experience high growth amid growing emphasis on promoting women’s health
  • Increasing prevalence of pelvic organ prolapse accelerating therapeutic approaches across China

Pelvic Congestion Syndrome Treatment Market- Prominent Drivers

  • Pelvic congestion syndrome treatment is accelerating on the back of rising genital cancers burden
  • Prospects for percutaneous transcatheter embolization are widening, providing significant impetus to market growth
  • Opportunities abound with respect to hormonal treatment for pelvic congestion syndrome cases

Pelvic Congestion Syndrome Treatment Market- Key Restraints

  • Limited knowledge about contemporary treatment approaches amongst patients is likely to hamper market growth
  • Expensive surgical procedures renders treatment unaffordable to moderate income patients, restricting penetration

Discover more about the pelvic congestion syndrome treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/3127/pelvic-congestion-syndrome-treatment-market

Competitive Landscape

Sanofi SA, TOLMAR Inc., Actiza Pharmaceuticals, Pfizer, Debio RP, AbbVie Inc., AstraZeneca, Novartis Pharmaceuticals Corporation, Indivior Inc., Pernix Ireland Pain Limited, ALZA Corporation and Fresenius Kabi USA LLC are some prominent pelvic congestion syndrome treatment players in the market. Manufacturers rely on launching new drug formulations to remain afloat in the market.

In August 2020, TOLMAR Pharmaceuticals Inc. enhanced its supply of its ELIGARD® (leuprolide acetate) drug for injectable suspension in all doses for patients undergoing palliative treatment for advanced prostate cancer. Simultaneously, it also enhanced its US manufacturing capacity to augment its FENSOLVI® injectable suspension to treat pediatric patients suffering from precocious puberty.

Capacity expansion is also assisting players in expanding their business prospects. For instance, in February 2021, Fresenius Kabi announced the establishment of two additional production facilities in Graz, Australia, as part of its commitment to expand its production and distribution of medicines in glass bottles and prefilled syringes, for a broad spectrum of drugs, including pelvic congestion syndrome treatment ones.

More Insights on the Pelvic Congestion Syndrome Treatment Market

In its latest report, Fact.MR offers unbiased analysis of the global pelvic congestion syndrome market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of disease type (primary pelvic congestion syndrome treatment & secondary pelvic congestion syndrome treatment), medication (NSAIDs, psychotherapy pelvic congestion syndrome treatment, analgesics pelvic congestion syndrome treatment, dihydroergotamine, progestins & others) and distribution channel (hospitals, diagnostic laboratories, gynecology clinics & ambulatory surgical centers) across seven regions (North America, Latin America, Western Europe, Eastern Europe, Japan, APEJ and Middle East & Africa)

Need more information about Report Methodology? Ask here

https://www.factmr.com/connectus/sample?flag=RM&rep_id=3127

Explore Fact.MR’s Coverage on the Healthcare Domain

Arterial Stents Market: Fact.MR’s extensive arterial stents market coverage sheds light on the prominent dynamics responsible for the expansion of the landscape for the upcoming decade. Information has been presented on the basis of prominent segments and their scope across key geographies. Additionally, details about prominent arterial stents manufacturers makes this report highly insightful and incisive.

Cardiopulmonary Stress Testing Systems Market: A detailed assessment of the global cardiopulmonary stress testing systems market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the global cardiopulmonary stress testing systems market along with their product portfolio enhances the reliability of this comprehensive research study.

Atopic Dermatitis Market: A detailed assessment of global atopic dermatitis drugs market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global atopic dermatitis drugs market along with their product portfolio enhances the reliability of this comprehensive research study.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
Sudip Saha
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR